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 Androgens are conjugated in the liver to glucuronides that are excreted in urine  
 Basolaterally located MRP3 is a high affinity transporter for androgen 
glucuronides 
 Apically located MRP2 is a low affinity transporter for androgen glucuronides 
 Apically located BCRP does not transport androgen glucuronides 





Several drug-metabolizing enzymes are known to control androgen homeostasis in 
humans. UDP-glucuronosyltransferases convert androgens to glucuronide conjugates 
in the liver and intestine, which enables subsequent elimination of these conjugated 
androgens via urine. The most important androgen is testosterone, while other 
important ones are the testosterone metabolites androsterone and etiocholanolone, 
and the testosterone precursor dehydroepiandrosterone. Epitestosterone is another 
endogenous androgen, which is included as a crucial marker in urine doping tests. 
Since glucuronide conjugates are hydrophilic, efflux transporters mediate their 
excretion from tissues. In this study, we employed the membrane vesicle assay to 
identify the efflux transporters for glucuronides of androsterone, 
dehydroepiandrosterone, epitestosterone, etiocholanolone and testosterone. The 
human hepatic and intestinal transporters MRP2 (ABCC2), MRP3 (ABCC3), MRP4 
(ABCC4), BCRP (ABCG2) and MDR1 (ABCB1) were studied in vitro. Of these 
transporters, only MRP2 and MRP3 transported the androgen glucuronides 
investigated. In kinetic analyses, MRP3 transported glucuronides of androsterone, 
epitestosterone and etiocholanolone at low Km values, between 0.4 and 4 µM, while 
the Km values for glucuronides of testosterone and dehydroepiandrosterone were 14 
and 51 µM, respectively. MRP2 transported the glucuronides at lower affinity, as 
indicated by Km values over 100 µM. Interestingly, the MRP2-mediated transport of 
androsterone and epitestosterone glucuronides was best described by sigmoidal 
kinetics. The inability of BCRP to transport any of the androgen glucuronides 
investigated is drastically different from its highly active transport of several estrogen 
conjugates. Our results explain the transporter mediated disposition of androgen 
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glucuronides in humans, and shed light on differences between the human efflux 
transporters MRP2, MRP3, MRP4, BCRP and MDR1. 
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Testosterone is the main androgen in humans, but also a drug and doping substance 
[1]. Multiple enzymes from several families including cytochrome P450s, 
hydroxysteroid dehydrogenases and oxidoreductases, sulfotransferases (SULT) and 
UDP-glucuronosyltransferases (UGT) regulate androgen homeostasis in the human 
body following their biosynthesis from cholesterol [2,3]. SULTs and UGTs are 
particularly important for excretion of androgens, since they produce androgen sulfates 
and glucuronides, respectively [3,4]. These conjugates are mostly inactive and 
excreted as such via urine. The UGTs that catalyze androgen glucuronidation are 
mainly expressed in the liver and intestine [5-7]. Conjugated steroids are too 
hydrophilic to passively cross cell membranes, and thus require active transporters for 
their excretion from cells [8,9]. 
Testosterone is converted to androsterone and etiocholanolone via several 
intermediate steps [3]. The latter two steroids are the main end products of androgen 
metabolism, and after conjugation with glucuronic acid, the androsterone and 
etiocholanolone glucuronides (androsterone-G and etiocholanolone-G, respectively, 
Fig. 1), are excreted in urine. Dehydroepiandrosterone is the precursor for biosynthesis 
of testosterone and testosterone-derived androgens, whereas epitestosterone is 
biosynthesized via a different pathway and is neither a metabolite nor a precursor of 
testosterone [2-4,10,11]. Although the physiological function of epitestosterone is 
currently unknown, and its biosynthesis rate is low compared with testosterone, it is a 
pivotal androgen for doping testing [10,11]. Large deviation from the urinary ratio of 
testosterone glucuronide to epitestosterone glucuronide (testosterone-G and 
epitestosterone-G, respectively), which is typically between one and two in urine, is 
utilized to detect the use of prohibited testosterone [11-13]. However, these 
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glucuronides are excreted in varying amounts in the population, and ratios clearly 
below one are mostly found in individuals that lack the UGT2B17 gene, which encodes 
UGT2B17, the main enzyme responsible for testosterone glucuronidation [5,12,14]. 
Nevertheless, ratios above four might be explained by decreased excretion of 
epitestosterone-G, although the comprehensive genetic basis for impaired excretion is 
unknown [5,15]. Currently, doping tests also include the androsterone-G to 
etiocholanolone-G ratio to accomplish a more comprehensive test for detecting the use 
of exogenous androgens [13]. 
Androgens are excreted in urine mainly as glucuronides, whereas free androgens are 
essentially absent from urine [4,12,14]. Androsterone-G and etiocholanolone-G are the 
main androgens in urine, while dehydroepiandrosterone glucuronide 
(dehydroepiandrosterone-G), epitestosterone-G and testosterone-G are about ten- to 
fifty-fold less abundant [12,16]. After administration of exogenous testosterone, 
androsterone-G and etiocholanolone-G are quantitatively the main testosterone 
metabolites in human urine and constitute almost the entire recovered dose [17]. The 
basal concentrations of androgen glucuronides in plasma are at nanomolar range [17-
20]. After the administration of exogenous testosterone, androgen glucuronides, 
particularly androsterone-G and etiocholanolone-G, may reach micromolar 
concentrations. However, glucuronide conjugates are formed intracellularly, and 
therefore the plasma concentrations do not fully reflect the intracellular concentrations 
[9,21]. The plasma and intracellular concentrations may differ, because the cell 
membrane restricts access of glucuronides to the systemic circulation from cells [8]. 
ATP-binding cassette (ABC) and solute carrier transporters are involved in disposition 
of steroid conjugates in human tissues [9,22-24]. Multidrug resistance-associated 
proteins 2, 3 and 4 (MRP2-4, gene ABCC2-4), multidrug resistance protein 1 (MDR1, 
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P-gp, gene ABCB1) and breast cancer resistance protein (BCRP, gene ABCG2) are 
the major transporters that mediate efflux of endogenous and exogenous compounds, 
including their glucuronide and sulfate conjugates, in the liver, intestine and kidney 
[9,25-27]. The role of MDR1 in disposition of glucuronide and sulfate conjugates is 
limited, while MRP2, MRP3 and BCRP have significant contributions in vivo [9,24,27]. 
MRP2, BCRP and MDR1 are expressed in apical membranes of hepatocytes and 
enterocytes, while MRP3 and MRP4 are localized at the opposite, basolateral, 
membranes of the same polarized cells [25,26]. The aforementioned transporters are 
studied in vitro in cell-based or vesicle-based assays of which only the latter assays 
can be used for hydrophilic compounds [28]. The vesicle-based assays provide 
qualitative data and are used to identify the active transporters toward the compounds 
in question. Furthermore, these assays allow characterization and comparison of the 
transport kinetics of individual transporters. The apparent affinities derived for 
transporters in vitro, along with current knowledge on expression levels of each 
transporter in tissues, provide evidence of the most active transporters in vivo. The 
vesicles are derived from either mammalian or insect cells that express recombinant 
human transporters [28]. Although some differences might occur between mammalian 
and insect cell derived transporter preparations, these discrepancies are normally 
reported as quantitative [29, 30]. However, the qualitative data remain unaffected. 
Estrogens and androgens share the same steroid backbone, while their A ring is 
different being planar and aromatic only in estrogens (Fig. 1 and 5). In addition, 
androgens have a second methyl group attached to carbon 10 and this group is not 
present in estrogens (Fig. 1). We have previously studied the transport of estrogen 
glucuronides by the aforementioned transporters and found high affinity transport by 
MRP3 and high active transport by BCRP [24]. However, due to the differences in their 
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structures, deducing transport activity for androgen glucuronides based on the 
knowledge of the transport of estrogen glucuronides is not feasible. 
The main aims of this study were to identify and characterize the hepatic human ABC 
transporters that contribute to efflux of androsterone-G, dehydroepiandrosterone-G, 
epitestosterone-G, etiocholanolone-G and testosterone-G (Fig. 1) in order to explain 
the mechanisms behind their in vivo disposition. An additional aim was to derive 
information on the structural elements in steroid conjugate transport, which affect 
individual transporters studied here. To this end, we tested the transport of these 
androgen glucuronides in vitro by employing the vesicular transport assay for the 




Figure 1. Structures of the androgen glucuronides investigated. Chemical 
structures and main biosynthesis pathways for the androgen glucuronides that were 


























































2. MATERIALS AND METHODS 
 
2.1 Chemicals and solvents 
Androsterone-G (100% purity), dehydroepiandrosterone-G (>99% purity), 
epitestosterone (100% purity) and testosterone-G (99% purity) were from Sigma-
Aldrich (St. Louis, MO, USA), while etiocholanolone-G was obtained from Steraloids 
(Newport, RI, USA). D3-testosterone-G was from the National Analytical Reference 
Laboratory (Australia). Epitestosterone-G was biosynthesized in-house as reported 
below. Formic acid and methanol were of analytical quality and obtained from Sigma-
Aldrich. Milli-Q water purification system including 0.22 μm filter (Merck Millipore, 
Darmstadt, Germany) was employed as the water source for analyses and assays. 
2.2 Biosynthesis of epitestosterone-G 
Recombinant human UGT2B7 expressed in Sf9 cells was applied for the biosynthesis 
of epitestosterone-G [5]. The final volume of enzyme reaction was 25 ml and contained 
750 µM epitestosterone, 7.5% (v/v) DMSO, 100 mM Tris-HCl buffer pH 7.5, 5 mM 
MgCl2, 4 mM uridine 5'-diphosphoglucuronic acid and 48.1 mg of protein from UGT2B7 
membrane preparation. After incubation for 24 hours in a 37 °C thermo-shaker, the 
suspension was centrifuged for 10 min at 16 000 g, the resulting pellet was washed 
twice with water and all three resulting supernatants were combined. Liquid-liquid 
extraction was employed to remove the unreacted epitestosterone by alkalizing the 
supernatant and extracting it twice with equal amount of dichloromethane. The 
aqueous phase was acidified with formic acid and loaded onto two separate 6 ml Oasis 
HLB (200 mg) cartridges from Waters (Milford, MA, USA). The Cartridges were washed 
with 4 ml of 35% methanol containing 2% formic acid, both v/v, and the glucuronide 
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fraction was subsequently eluted with 75% methanol containing 5% ammonia, both 
v/v. After evaporation, the eluate was dissolved in a mixture of methanol and water, 
and subjected to high performance liquid chromatography purification. The fractions 
corresponding to epitestosterone-G were collected, combined and evaporated. The 
final yield of the reaction was 70% (n/n) resulting in 6.3 mg of epitestosterone-G. 
Nuclear magnetic resonance (NMR) spectra were obtained for epitestosterone-G in 
DMSO-d6 employing Ascend 400 MHz spectrometer from Bruker (Billerica, MA, USA), 
and the chemical shifts of spectra were related to the residual DMSO peak (Fig. S1-
S5). High-resolution mass spectrometric analysis at negative electrospray ionization of 
epitestosterone-G resulted in 463.231 ([M-H]-) m/z (calculated 463.234). 
2.3 Vesicular transport assays 
Inside-out membrane vesicles from Sf9 insect cells expressing the human recombinant 
transporters MRP2, MRP3, MRP4, BCRP, MDR1 or a transport defective mutant of 
MRP3 for control preparations (CTRL) were prepared as reported previously [31,32]. 
BCRP and MDR1 vesicles were loaded with cholesterol to enhance the transport 
activity as reported and described previously [30,31,33]. We have previously reported 
the proper functionality of the aforementioned human transporters in our Sf9 vesicle-
based assay [24,31,32]. 
The vesicular transport assays were carried out in 96-well plates as previously 
described [24,31]. Transporter vesicles, 40 µg of total membrane protein, were 
suspended in a total volume of 50 µl of the transport assay mixture (40 mM MOPS 
adjusted to pH 7.0 with Tris–HCl, 6 mM MgCl2 and 60 mM KCl) containing the 
androgen glucuronide to be tested, on ice. The suspension was incubated for 10 min 
on a shaker adjusted to 500 rpm and at a temperature of +37 °C. The transport 
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reactions were initiated by adding 25 µl of the transport assay mixture containing ATP 
(+ATP samples) or no ATP (-ATP samples), bringing the reactions to a final volume of 
75 µl. The final concentration of ATP was 4 mM, while the concentrations of androgen 
glucuronides are stated in each figure legend. The transport reaction was then 
incubated on the shaker for a pre-determined time (see figure legends). The transport 
reactions were terminated by adding 200 µl of cold wash buffer (40 mM MOPS adjusted 
to pH 7.0 with Tris HCl and 70 mM KCl) to each well and by transferring the samples 
to a filter plate that was kept under vacuum. Each well on the filter plate was then 
washed five times with 200 µl of the cold wash buffer. The filter plate was dried at room 
temperature, after which androgen glucuronides were eluted from the wells with 100 
µl of 75% methanol containing 0.1% formic acid (both v/v), and an internal standard 
(Table 1). The eluted samples were analyzed by LC-MS/MS as described below 
(Section 2.4). 
The stock solutions of the androgen glucuronides were prepared in DMSO at 50 mM 
and stored at -20 °C. Subsequent dilutions were prepared in the transport assay buffer 
so that the final DMSO concentration was below 0.1% (v/v) in the single substrate 
concentration assays and 1% (v/v) in the kinetic assays. Before conducting the kinetic 
assays, the solubility of the androgen glucuronides in the transport assay mixture, over 
the entire concentration range used in the assays, was ensured by employing high-
performance liquid chromatography with UV detection. To exclude any artifacts during 
the assay such as disruption of the vesicles, -ATP values from the transport kinetic 
assays were examined against the concentrations of the androgen glucuronides. A 
linear fitting of these data was then performed, which resulted in R2 values of 0.99 or 
higher for all the kinetic assays. 
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For the transport kinetic assays, the linear time range of transport was determined and 
the transport assay time was selected based on that range (Fig. S7). The transport 
kinetic data is presented as ATP-dependent values that are derived by subtracting the 
-ATP (passive and unspecific transport) from +ATP (transporter-mediated, passive and 
unspecific transport) values and combining the standard deviations. The data were 
fitted to either the Michaelis-Menten equation (v = Vmax[S]/([S] + Km)) or to the Hill 
equation (v = Vmax[S]h/((S50)h + [S]h)), where Vmax represents the maximal transport 
rate, [S] is the substrate concentration, Km represents the Michaelis constant, S50 is 
the concentration producing half-maximal reaction rate and h is the Hill coefficient. 
2.4 Analytical methods 
ACQUITY UPLC I Class Ultra Performance Liquid Chromatography connected to Xevo 
TQ-S triple quadrupole mass spectrometry, both from Waters, were employed for 
quantification of androgen glucuronides in the vesicle assay samples. Samples, 0.5-4 
µl, were injected into Acquity UPLC BEH C18 column (2.1×100 mm, 1.7 μm from 
Waters) that was kept at 50 °C and operated at a flow rate of 0.4 ml/min. The 
chromatographic eluents were water (A) and methanol (B) both with 0.1% (v/v) formic 
acid. The method was 0-1 min (60% B), 1-2.5 min (60->95% B), 2.5-3.5 (95% B) and 
3.5-4.5 min (60% B). Negative electrospray ionization was employed in the mass 
spectrometry with the following parameters: -2.5 kV capillary voltage, 1 V cone, 100 V 
source offset, 150 °C source temperature, 600 °C desolvation gas temperature, 150 
and 900 l/hr cone and desolvation gas flow, 6 bar nebulizer gas flow and 0.09 ml/min 
collision gas flow. The ion source gas and collision gas were nitrogen and argon, 
respectively, both from Aga (Espoo, Finland). The mass transitions, collision energies, 
dwell times, retention times and internal standards for the analytes are presented in 
Table 1. The analyte to internal standard ratio was employed for quantification. Fresh 
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standard curve was prepared for each experiment, similarly to the actual samples, that 
is in 100 µl of the elution solvent, incubated on a pre-wetted filter plate and centrifuged 
to a collection plate. The standard range curve was adjusted to each experiment in 
order to cover all samples and was typically in the range of 0.5 nM to 1000 nM. 
 
Table 1. Mass spectrometry parameters, retention times and internal standards 
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3.1 MRP2, MRP3, MRP4, BCRP and MDR1 transport of androgen glucuronides 
The transport of androsterone-G, dehydroepiandrosterone-G, epitestosterone-G 
etiocholanolone-G and testosterone-G (see structures in Fig. 1) by human MRP2, 
MRP3, MRP4, BCRP and MDR1 was first assayed at two single substrate 
concentrations, 1 µM (Fig. 2) and 50 µM (Fig. S6). In the presence of ATP (+ATP), the 
uptake of 1 µM androsterone-G, dehydroepiandrosterone-G, epitestosterone-G 
etiocholanolone-G and testosterone-G into MRP3 vesicles was 17-, 2-, 34-, 34- and 9-
fold (Fig. 2), respectively, higher than in the absence of ATP (-ATP). For MRP2, the 
respective values were 1.4, 6, 3, 5 and 5 (Fig. 2). The -ATP data represent passive 
transfer of a compound into vesicles and unspecific binding, while the +ATP data also 
include the active transport. These data indicate that MRP3 transports efficiently all the 
glucuronides investigated, except dehydroepiandrosterone-G (Fig. 2B), while MRP2 
transports similarly all the glucuronides with the exception of androsterone-G (Fig. 2A). 
Although MRP2-mediated transport of 1 µM androsterone-G was similar to CTRL 
vesicles (Fig. 2A), at 50 µM substrate concentration (Fig. S6A) this transport was two-
fold higher in the +ATP samples in comparison to the –ATP samples. This suggests 
that androsterone-G is a low affinity substrate for MRP2.  
The transport ratio (+ATP/-ATP) of the glucuronides studied into MRP4 vesicles was 
below two and similar to the ratio in CTRL vesicles, which indicates negligible 
contribution of MRP4 in the transport of androgen glucuronides (Fig. 2). Furthermore, 
the transport ratios of the androgen glucuronides investigated into BCRP and MDR1 
vesicles were also close to two (Fig. 2) and similar to the transport observed into their 
control vesicles (CTRL+C). This indicates negligible contribution of these two 
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transporters as well. Higher endogenous transport in these cholesterol enriched Sf9-
derived mock vesicles has been reported earlier [34]. 
Figure 2. Human efflux transporters in the transport of androgen glucuronides. 
The assays were conducted at 1 µM substrate concentration for 3 min in the presence 
of ATP (+ATP) or in its absence (-ATP). The total protein amount of membrane vesicles 
was 40 µg per sample. BCRP and MDR1 as well as their control vesicles CTRL+C 
were supplemented with cholesterol as described in the Materials and Methods. The 




























































































































































































































































3.2. Characterization of MRP2 and MRP3 transport kinetics of androgen 
glucuronides 
MRP2 and MRP3 transported all the glucuronides in a time-dependent matter (Fig. 
S7), and hence concentration-depend transport was characterized for all the 
glucuronides by both transporters. The kinetic analyses revealed that MRP3 
transported androsterone-G, epitestosterone-G and etiocholanolone-G at low 
micromolar Km values, while the transport of testosterone-G was at somewhat lower 
apparent affinity since its Km value was above ten micromolar (Fig. 3A, 3B and Table 
2). The MRP3-mediated transport of dehydroepiandrosterone-G was clearly weakest 
for this transporter in comparison to other androgen glucuronides tested, as seen from 
the high Km and low Vmax values (Fig. 3C and Table 2). 
 
Figure 3. MRP3 transport kinetics of the androgen glucuronides. The Y-axis 
values were derived by subtracting the transport values without ATP (-ATP) from the 
values in the presence of ATP (+ATP), resulting in ATP-dependent transport rates. The 
lines represent the fitting of the data to the Michaelis-Menten equation (see the fitted 
parameters in Table 2). The inset of panel B presents transport kinetics of 
etiocholanolone-G at the lower concentrations. The transport reaction times were 
selected based on the time-linearity results (Fig. S7) and were 1 min, except 3 min for 
dehydroepiandrosterone-G. The total protein amount of membrane vesicles was 40 µg 
per sample. The results are from an experiment in triplicate samples and the error bars 
represent ±S.D. 
 
In contrast to MRP3, the MRP2 transport of all the glucuronides tested occurred at 
clearly higher Km values, over 100 micromolar, but also at higher Vmax values (Fig. 4 
and Table 2). The MRP2 transport of androsterone-G and epitestosterone-G exhibited 

























































































































































sigmoidal kinetics, and thus these data were fitted to the Hill equation (Fig. 4A, 4B and 
Table 2). MRP2 transport of dehydroepiandrosterone-G, etiocholanolone-G and 
testosterone-G were fitted to the Michaelis-Menten equation (Fig. 4 and Table 2). The 
kinetic curve for testosterone-G transport by MRP2 did not saturate within the 
concentration range tested (Fig. 4A). Hence, the fitted kinetic constants represent the 
best estimates based on the available data (Table 2). 
 
Figure 4. MRP2 transport kinetics of the androgen glucuronides. The Y-axis 
values were derived by subtracting the transport values without ATP (-ATP) from the 
values in the presence of ATP (+ATP), resulting in ATP-dependent transport rates. The 
lines represent the fitting of the data to the Michaelis-Menten equation or to the Hill 
equation in the case of androsterone-G and epitestosterone-G (see the fitted 
parameters in Table 2). The transport reaction times were selected based on the time-
linearity results (Fig. S7) and were 2 min (etiocholanolone-G), 4 min 
(dehydroepiandrosterone-G, epitestosterone-G and testosterone-G) or 6 min 
(androsterone-G). The total protein amount of membrane vesicles was 40 µg per 































































































































































Table 2. The derived transport kinetic parameters for MRP2 and MRP3. 
 MRP2 MRP3 
Androgen glucuronide Km (95% CI),  
µM 
Vmax (95% CI), 
pmol/min/mg 
vesicle protein 
Km (95% CI), 
µM 
Vmax (95% CI), 
pmol/min/mg 
vesicle protein 
Androsterone-G S50=160  
(114-206) 















































The experimental data (Fig. 3 and 4) were fitted to the Michaelis-Menten equation, 
except in the cases of MRP2 transport of androsterone-G and epitestosterone-G where 














In this work, we investigated the five main ABC transporters that were expected to be 
involved in the transport of androgen glucuronide conjugates in the liver. Our results 
are significant for understanding molecular mechanisms in disposition of the androgen 
glucuronides studied. In addition, our results reveal new aspects on the specificity of 
MRP2, MRP3, MRP4 and BCRP to several androgen glucuronides. 
 
4.1 Implications of structural features in androgen glucuronides for their efflux 
transport 
Previously, we have shown that endogenous estrogen glucuronides are excellent 
substrates for BCRP and MRP3, while MRP2 is a low-affinity transporter and MRP4 
transports selectively only some of the glucuronides [24,31]. Here, our results show 
that none of the androgen glucuronides tested are substrates for BCRP (Fig. 2), 
suggesting that the BCRP-mediated transport of steroid conjugates is dependent on 
the presence of a flat aromatic A ring in the substrate, which androgens lack in their 
steroid backbone (Fig. 1 and 5). In contrast, MRP2 and MRP3 transport both androgen 
and estrogen glucuronides, and thus exhibit lower selectivity in the transport of steroid 
glucuronides. This suggests that the aromatic A ring or its effect on the flatness of 
steroid structure are not essential for the transport activity of MRP2 and MRP3 (Fig. 2-
4) [24]. We show here that MRP3 transports androgen glucuronides at even lower Km 
values (Table 2) than estrogen glucuronides (the Km values of estrogen glucuronides 
were between 3-18 µM [24]), while in the case of MRP2 the Km values of both estrogen 
glucuronides (the Km values were between 180-790 µM [24]) and androgen 




Figure 5. Three-dimensional conformations of androgen and estrogen 
glucuronides. Oxygens are colored in red, while non-polar hydrogens are omitted. 
The glucuronic acid moieties of the compounds are faint in relation to the rest of the 
structure for clarity. Estradiol-3-glucuronide is included to present a substrate of BCRP 
[24]. The structures were prepared with PyMOL [45]. 
 
The transport affinity of MRP3 is highest for androsterone-G, epitestosterone-G and 
etiocholanolone-G (Table 2). In these compounds, the glucuronic acid moiety points 
towards the opposite direction of the bulky methyl groups of the steroid backbone (Fig. 
5). Furthermore, the A ring of etiocholanolone-G is at almost a right angle with respect 
to the steroid backbone, which results in even less flat structure and placing the 
glucuronide acid out of the plane at a higher angle (Fig. 5). This structure had the 
highest affinity to MRP3, resulting in a 10-fold lower Km value than for androsterone-G 
that is otherwise structurally similar to etiocholanolone-G but with less bent A ring 
(Table 2, Fig. 5). The glucuronic acid moieties of dehydroepiandrosterone-G and 
White = Estradiol-3-glucuronide
Yellow = Dehydroepiandrosterone-G






testosterone-G point towards the same direction as the bulky methyl groups and these 
two compounds have almost an order of magnitude higher Km values for MRP3. MRP2, 
on the other hand, exhibited overall lower affinities for androgen glucuronides, and thus 
was less affected by differences in the steroid backbone. This might indicate a more 
flexible binding site and wide compound acceptance for MRP2. Interestingly, its 
transport of androsterone-G and epitestosterone-G showed sigmoidal kinetics (Fig. 4A, 
4B and Table 2). Sigmoidal transport kinetics by MRP2 have been reported also for 
another steroid conjugate, estradiol-17-glucuronide [31,35]. Together, differences in 
the selectivity of MRP2, MRP3 and BCRP may have significant implications for the 
disposition and excretion of steroid metabolites in humans. 
 
4.2 Efflux transporters in the disposition of androgen glucuronides 
Androgens are mostly excreted as conjugates and the biliary excretions of 
androsterone, dehydroepiandrosterone and etiocholanolone are clearly below ten 
percent, while for testosterone it is slightly above ten percent [3,36-38]. On the other 
hand, the biliary excretion of the main estrogens is much higher and could comprise 
half of their total excretion [38]. Since glucuronide conjugates are the main metabolites 
for most androgens and estrogens, the difference in biliary excretion could partly be 
explained by the low BCRP and high MRP3 transport of androgen glucuronides, 
because BCRP efficiently transports only estrogen glucuronides (Fig. 2 and Table 2) 
[24]. For androgens, this appears to result in higher basolateral efflux transport to the 
systemic circulation compared with excretion to bile, while estrogens are more likely to 
be transported in bile than androgens. 
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Epitestosterone-G and testosterone-G are excreted physiologically in urine in similar 
amounts, resulting typically in testosterone-G to epitestosterone-G ratio between one 
and two, although among individuals this ratio varies from below one up to five [12]. 
Interestingly, the endogenous production of epitestosterone is only about 3% of the 
testosterone’s biosynthesis, while the urinary excretion of their glucuronides (mass per 
day) is almost equal, indicating more efficient formation and excretion of 
epitestosterone-G to urine [10]. Rapid excretion of epitestosterone-G, the main 
metabolite of epitestosterone, in urine is found also after exogenous administration of 
epitestosterone [10,19,39]. Testosterone is also metabolized rapidly after exogenous 
administration and subsequently testosterone-G is excreted in urine quickly, but it 
comprises only a few percent of the total testosterone metabolites [17]. In addition, 
testosterone conjugates are excreted in bile to some extent, which leads to excretion 
of unconjugated testosterone via feces [36,38]. Our results indicate that apical (MRP2) 
and basolateral (MRP3) efflux transporters control the excretion of epitestosterone-G 
and testosterone-G differently (Fig. 2C, 2E and Table 2). MRP3 transports 
epitestosterone-G 10-fold more efficiently than testosterone-G, while MRP2 transports 
both glucuronides similarly but at much lower apparent affinity than MRP3 (Fig. 3A, 4A 
and Table 2). These results suggest that MRP3 contributes to systemic excretion of 
epitestosterone-G and testosterone-G from the liver and intestine, while MRP2 may 
transport particularly some testosterone-G in bile. These differences may affect the 
excretion of testosterone-G and epitestosterone-G, and their ratio in urine. 
Androsterone-G and etiocholanolone-G are the end metabolites of androgens and the 
main metabolites of testosterone [3,4,17]. Only a few percent of androsterone and 
etiocholanolone are excreted in bile and none in feces after exogenous administration 
of these steroids, while neither is excreted in bile after testosterone administration [37]. 
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The low biliary and intestinal excretion of androsterone-G and etiocholanolone-G could 
be explained by our results showing that MRP2 has a low affinity towards these 
glucuronides (Fig. 2A, 2D, 4B, Table 2). On the other hand, androsterone and 
etiocholanolone are excreted rapidly in urine within a few hours as glucuronides 
following their intravenous administration or after administration of oral testosterone 
[17,20,37]. In particular, etiocholanolone-G appears more rapidly in the plasma and is 
eliminated faster than androsterone-G. The rapid urinary excretion of these 
glucuronides is explained by the high affinity transport of MRP3 in comparison to 
MRP2, and the high affinity MRP3-mediated transport of etiocholanolone-G in 
comparison to androsterone-G that appears to correspond to the faster excretion of 
the former metabolite (Fig. 3B, 4B, Table 2). To the best of our knowledge, the renal 
clearances of androgen glucuronides have not been comprehensively investigated. 
However, one study suggests that androsterone-G and etiocholanolone-G are 
excreted by filtration in the kidney [40]. It should be noted that UGT2B7 is also 
expressed in the kidney, and thus this enzyme might contribute to the glucuronidation 
of androsterone and etiocholanolone, alongside the hepatic and intestinal UGT2B7 
and UGT2B17 [6,7]. However, quantitative contribution of different tissues to systemic 
glucuronidation of androsterone and etiocholanolone are not currently understood. 
Dehydroepiandrosterone-G is present in the plasma and urine at much lower levels 
than the corresponding sulfate conjugate [16,18,41]. Interestingly, for androsterone the 
opposite is true, although the same enzyme, SULT2A1, catalyzes sulfation of both 
compounds with similar efficiency [16,41-43]. The reasons behind the small fraction of 
dehydroepiandrosterone-G in plasma and urine in comparison to 
dehydroepiandrosterone sulfate are unknown, particularly since the UGTs that 
catalyze dehydroepiandrosterone glucuronidation have not been identified, yet. Based 
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on the results of our current study, the hepatic basolateral efflux for 
dehydroepiandrosterone-G may be low (Table 2). In comparison to androsterone-G 
and epitestosterone-G, the in vitro clearance value of MRP3 is 50-fold lower for 
dehydroepiandrosterone-G, which might contribute to low systemic and urinary 
concentrations of dehydroepiandrosterone-G (Table 2). 
While our manuscript was under preparation, Li and colleagues (2019) published 
transport data on androsterone-G, dihydrotestosterone glucuronide, etiocholanolone-
G and testosterone-G [44]. Our results are in line with their observations that MRP2 is 
a low affinity and MRP3 a high affinity transporter for androgen glucuronides, while 
MRP4 and BCRP do not transport these conjugates. Our study also includes 
dehydroepiandrosterone-G and epitestosterone-G and thereby enhances significantly 
the understanding of androgen glucuronide disposition and provides further insights 
into structural features that affect steroid conjugate transport by the important human 
efflux transporters. In addition, our results reveal new aspects on the formation of 
urinary testosterone-G to epitestosterone-G ratio, which is commonly close to one 
despite a large difference in the biosynthesis rate of these two androgens. This ratio is 
crucial for detecting testosterone-doping abuse and it is important to understand its 









We studied here the efflux transport of important androgen conjugates androsterone-
G, dehydroepiandrosterone-G, epitestosterone-G, etiocholanolone-G and 
testosterone-G. Our results reveal that MRP3 transports these conjugates at low Km 
values, while the corresponding values for MRP2 are over a magnitude higher. In 
particular, the MRP3 transport of androsterone-G, epitestosterone-G and 
etiocholanolone-G resulted in Km values of 3.5, 1.9 and 0.36 µM, which indicates a 
major role for this hepatic and intestinal basolateral transporter in the disposition of 
these androgen glucuronides in humans. In addition, we show that BCRP does not 
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Figures S1-S5 present nuclear magnetic resonance (NMR) analyses of epitestosterone-
G that was biosynthesized in our laboratory (see Materials and Methods of the main text)
Figure S6 shows transport results for all the tested androgen glucuronides at 50 µM
concentration, whereas in the main text the results for 1 µM substrate concentration are
shown. The experimental details are presented in Figure 2 and Materials and Methods
section of the main text .
Figure S7 presents results of time-dependent transport assays, for both MRP2 and
MRP3, each one with all the tested substrates. The experimental details are same as are
presented in Figure 2 and Materials and Methods section of the main text, except the













































































































FIGURE S1.  1H NMR spectrum of epitestosterone-G
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FIGURE S3. 1H-13C Heteronuclear Single Quantum Correlation  - Distortionless Enhancement by Polarization 



























































































































































































































































































































































































































FIGURE S6. Human efflux transporters in the transport of 50 µM androgen glucuronides.
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FIGURE S7.  MRP2 and MRP3 time-dependent transport of 10 µM androgen glucuronides
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